CD8A and cancer: These studies altogether support cancer cells or Tu-sEVs may be genetically engineered to enhance antitumor responses of Tu-sEV-based vaccines via elevated levels of immunostimulatory antigen and molecule expressions as well as both CD4+ and CD8+ T cells.